文献速递妇科

子宫内膜癌的免疫组化分子风险分类:一种实用且高可重复性的方法

The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method.
PubMed 文献 · Gynecol Oncol · 2022-03-24

该回顾性研究对778例术前子宫局限型子宫内膜癌进行免疫组化分析,依据错配修复状态和p53突变定义3组人群,发现其与FIGO分期、分级、组织类型、LVSI、肌层浸润及肿瘤大小显著相关,并与ESGO-ESMO-ESP 2021风险分类及总生存和无病生存相关。

要点

  • 免疫组化可将子宫内膜癌分为错配修复稳定、错配修复不稳定和p53突变3组人群。
  • 3组免疫组化人群与FIGO分期、分级、组织类型、LVSI、肌层浸润及肿瘤大小显著相关。
  • 3组免疫组化人群与ESGO-ESMO-ESP 2021风险分类及总生存、无病生存相关。

核心结论

  • 在该大样本系列中,实用且系统地使用免疫组化可能在按组织学特征和临床结局正确分层子宫内膜癌患者方面具有重要作用。

研究设计与样本

  • 回顾性免疫组化分析,纳入778例术前子宫局限型子宫内膜癌,检测MLH1、MSH2、MSH6和PMS2以定义错配修复稳定或不稳定表型,并检测p53突变及其他分子特征。

主要发现

  • 基于免疫组化评估定义3组子宫内膜癌人群:错配修复稳定患者、错配修复不稳定患者和p53突变患者。
  • 免疫组化分层与FIGO分期(p < 0.001)、分级(p < 0.001)、组织类型(p < 0.001)、LVSI presence(p < 0.001)、肌层浸润和肿瘤大小(两者p = 0.003)统计学相关。
  • 3组免疫组化人群统计学反映ESGO-ESMO-ESP 2021子宫内膜癌风险分类(p < 0.001)。
  • Kaplan-Meier曲线在总生存和无病生存方面也证实上述结果(p < 0.0001)。
  • 多因素分析显示,雌激素受体(ER)缺失影响总生存(p = 0.011),年龄>60岁和ER状态影响无病生存(p = 0.041和p = 0.004)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of this study is to assess the clinical reproducibility and the potential oncological validity of the molecular information provided by the immunohistochemistry (IHC) to properly stratify the endometrial cancer patients. METHODS: Retrospective IHC analyses were conducted in a large series of 778 pre-operative uterine-confined ECs, studying the presence/absence of MLH1, MSH2, MSH6 and PMS2 to define the mismatch repair (MMR) stable or instable phenotype; the presence of p53 mutations and other molecular features. The molecular profile was correlated with histological, clinical and prognostic data. RESULTS: Based on IHC assessment, we defined 3 EC populations: stable MMR patients (MMRs), instable patients (MMRi) and p53 mutated patients (p53+). Our result demonstrated that the IHC stratification statistically correlated with the most relevant pathologic-clinical features: FIGO stage (p < 0.001), grading (p < 0.001), histotype (p < 0.001), presence of LVSI (p < 0.001), myometrial invasion and tumor dimension (p = 0.003 for both). These 3 IHC populations statistically reflected the EC risk class ESGO-ESMO-ESP classification 2021 (p < 0.001). These results were also confirmed in the Kaplan-Meier curves in terms of overall survival (OS) and disease-free survival (DFS) (p < 0.0001). The multivariate analyses demonstrated that absence of estrogen receptor (ER) impacted the OS (p = 0.011) and, the Age > 60 years and the ER-status the DFS (p = 0.041 and p = 0.004). CONCLUSION: In this large series, we demonstrated that the pragmatic and systematic use of IHC may have an important role to properly stratify, in terms of histological features and clinical outcomes, the EC patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Perrone E, De Felice F, Capasso I, et al. The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method. Gynecol Oncol. 2022. PMID: 35341588. doi:10.1016/j.ygyno.2022.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。